Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3243 Target Snapshot

Receptor-type tyrosine-protein phosphatase C · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
1,331Compounds
109Assays
0Approved Drugs
2,105.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Receptor-type tyrosine-protein phosphatase C shows clinical signal disease relevance led by acute lymphoblastic leukemia. 4 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P08575. Start with acute lymphoblastic leukemia, then reuse UniProt P08575 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with acute lymphoblastic leukemia, then reuse UniProt P08575 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
acute lymphoblastic leukemia

Receptor-type tyrosine-protein phosphatase C shows clinical signal disease relevance led by acute lymphoblastic leukemia. 4 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with acute lymphoblastic leukemia because it currently carries clinical signal support. Linked drugs include AHN-12. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Clinical signal Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Receptor-type tyrosine-protein phosphatase C as ChEMBL target CHEMBL3243, mapped to UniProt P08575. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Receptor-type tyrosine-protein phosphatase C
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3243
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P08575
Receptor-type tyrosine-protein phosphatase C
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Receptor-type tyrosine-protein phosphatase C is the right protein anchor across sources, using UniProt P08575 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why acute lymphoblastic leukemia is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameReceptor-type tyrosine-protein phosphatase C
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP08575
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelReceptor-type tyrosine-protein phosphatase C
UniProt AccessionP08575
Component TypeProtein
Sequence Length1306 aa

Receptor-type tyrosine-protein phosphatase C

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Receptor-type tyrosine-protein phosphatase C, mapped to UniProt P08575. Sequence length is 1306 aa.

Mapped IDP08575
Review nameReceptor-type tyrosine-protein phosphatase C
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Clinical signal Open Targets-ready proxy

Receptor-type tyrosine-protein phosphatase C shows clinical signal disease relevance led by acute lymphoblastic leukemia. 4 more disease programs remain visible in the same review block.

Clinical signal Phase I
acute lymphoblastic leukemia
1 linked drug · 1 direct · 1 efficacy
Linked drugAHN-12
Clinical signal Phase I
acute myeloid leukemia
1 linked drug · 1 direct · 1 efficacy
Linked drugAHN-12
Clinical signal Phase I
chronic myelogenous leukemia
1 linked drug · 1 direct · 1 efficacy
Linked drugAHN-12
Clinical signal Phase I
leukemia
1 linked drug · 1 direct · 1 efficacy
Linked drugAHN-12
Clinical signal Phase I
myelodysplastic syndrome
1 linked drug · 1 direct · 1 efficacy
Linked drugAHN-12
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with acute lymphoblastic leukemia because it currently carries clinical signal support. Linked drugs include AHN-12. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseacute lymphoblastic leukemia
Strongest levelClinical signal
Block modeOpen Targets-ready proxy
Assay Mix

Activity Type Distribution

IC501,229.0
KI876.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL200117 6.82 IC50 150.0 Preclinical
CHEMBL51314 6.7 IC50 200.0 Preclinical
CHEMBL89067 6.55 IC50 280.0 Preclinical
CHEMBL515797 6.55 IC50 280.0 Preclinical
CHEMBL51776 6.52 IC50 300.0 Preclinical
CHEMBL567069 6.52 IC50 300.0 Preclinical
CHEMBL51781 6.4 IC50 400.0 Preclinical
CHEMBL51579 6.4 IC50 400.0 Preclinical
CHEMBL417727 6.4 IC50 400.0 Preclinical
CHEMBL52491 6.4 IC50 400.0 Preclinical
Distribution

pChEMBL Value Distribution

52
5.0
49
5.5
61
6.0
6
6.5
0
7.0
0
7.5
0
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Assay Landscape

Assay Landscape

109
Total Assays
268
Tested Compounds
2
Assay Types
Binding — 108 assays, 268 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 84 216 5.4
assay format 12 45 4.8
cell-based format 12 7 4.8
ADME — 1 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine